Orexo Future Growth

Future criteria checks 5/6

Orexo is forecast to grow earnings and revenue by 75.5% and 13.9% per annum respectively. EPS is expected to grow by 75.5% per annum. Return on equity is forecast to be 36.7% in 3 years.

Key information

75.5%

Earnings growth rate

75.5%

EPS growth rate

Pharmaceuticals earnings growth	48.5%
Revenue growth rate	13.9%
Future return on equity	36.7%
Analyst coverage	Low
Last updated	25 Apr 2024

Recent future growth updates

Recent updates

Orexo AB (publ)'s (STO:ORX) Business And Shares Still Trailing The Industry

Apr 03

We Think Orexo (STO:ORX) Has A Fair Chunk Of Debt

Dec 09

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 24% Below Its Share Price

Jun 14

Is Orexo (STO:ORX) A Risky Investment?

Apr 27

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 92% Above Its Share Price

Oct 19

Increases to Orexo AB (publ)'s (STO:ORX) CEO Compensation Might Cool off for now

Apr 06

Orexo (STO:ORX) Share Prices Have Dropped 22% In The Last Five Years

Mar 16

Nikolaj Sørensen Is The President & CEO of Orexo AB (publ) (STO:ORX) And They Just Picked Up 2.1% More Shares

Feb 17

Orexo AB (publ) (STO:ORX) Just Reported And Analysts Have Been Cutting Their Estimates

Jan 31

Earnings and Revenue Growth Forecasts

OM:ORX - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	910	45	99	110	1
12/31/2025	788	-29	10	18	1
12/31/2024	617	-107	-29	-26	1
12/31/2023	639	-128	-114	-95	N/A
9/30/2023	629	-201	-172	-141	N/A
6/30/2023	634	-195	-205	-180	N/A
3/31/2023	624	-218	-176	-157	N/A
12/31/2022	624	-178	-180	-157	N/A
9/30/2022	612	-152	-203	-188	N/A
6/30/2022	597	-177	-241	-207	N/A
3/31/2022	592	-216	-285	-243	N/A
12/31/2021	565	-223	-282	-229	N/A
9/30/2021	580	-207	-239	-160	N/A
6/30/2021	585	-240	-201	-93	N/A
3/31/2021	621	-198	-281	-79	N/A
12/31/2020	664	-84	-173	17	N/A
9/30/2020	743	4	-94	84	N/A
6/30/2020	824	201	89	231	N/A
3/31/2020	846	288	248	284	N/A
12/31/2019	845	219	255	287	N/A
9/30/2019	834	232	286	302	N/A
6/30/2019	819	182	192	194	N/A
3/31/2019	818	178	183	187	N/A
12/31/2018	783	138	238	242	N/A
9/30/2018	747	113	144	147	N/A
6/30/2018	697	79	212	215	N/A
3/31/2018	656	32	223	225	N/A
12/31/2017	644	23	145	147	N/A
9/30/2017	637	19	N/A	241	N/A
6/30/2017	653	27	N/A	191	N/A
3/31/2017	682	29	N/A	151	N/A
12/31/2016	706	29	N/A	156	N/A
9/30/2016	752	-57	N/A	84	N/A
6/30/2016	710	-139	N/A	-38	N/A
3/31/2016	648	-229	N/A	-82	N/A
12/31/2015	646	-210	N/A	-109	N/A
9/30/2015	636	-95	N/A	-116	N/A
6/30/2015	627	-85	N/A	-188	N/A
3/31/2015	617	-51	N/A	-381	N/A
12/31/2014	570	-57	N/A	-487	N/A
9/30/2014	449	-146	N/A	-593	N/A
6/30/2014	440	-138	N/A	-671	N/A
3/31/2014	391	-204	N/A	-358	N/A
12/31/2013	429	-155	N/A	-263	N/A
9/30/2013	413	-139	N/A	-227	N/A
6/30/2013	369	-141	N/A	-64	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ORX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).

Earnings vs Market: ORX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ORX is expected to become profitable in the next 3 years.

Revenue vs Market: ORX's revenue (13.9% per year) is forecast to grow faster than the Swedish market (1.7% per year).

High Growth Revenue: ORX's revenue (13.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ORX's Return on Equity is forecast to be high in 3 years time (36.7%)

Orexo Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 127%

No longer forecast to breakeven

Forecast breakeven date pushed back to 2025

Price target decreased by 15% to kr31.00

Consensus forecasts updated

Recent updates

Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US

Orexo AB (publ)'s (STO:ORX) Business And Shares Still Trailing The Industry

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 127%

Orexo AB (Publ) Announces Board Resignations

President & CEO recently bought kr148k worth of stock

New major risk - Financial position

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Orexo AB (publ) to Report Q4, 2024 Results on Feb 06, 2025

We Think Orexo (STO:ORX) Has A Fair Chunk Of Debt

Orexo AB (Publ) Announces FDA Acceptance of New Drug Application Filing for OX124

Orexo AB (Publ) Announces FDA Acceptance of New Drug Application Filing for OX124

Independent Chairman of the Board recently bought kr361k worth of stock

No longer forecast to breakeven

Executive VP & CFO recently bought kr81k worth of stock

Third quarter 2023 earnings: Revenues exceed analyst expectations

Orexo AB (publ) Announces Changes in the Board of Directors

Orexo AB (publ), Annual General Meeting, Apr 26, 2024

Orexo AB (publ) Announces Data from the MODIA Study Evaluating Impact on Use of Illicit Opioids

Orexo AB (Publ) Announces Henrik Kjær Hansen Will Resign from the Board of Directors

Orexo AB (publ) to Report Q2, 2024 Results on Jul 17, 2024

Orexo AB (publ.) Submits New Drug Application to FDA for OX124, a High-Dose Rescue Medication for Opioid Over Overio Overio Overio Overio

President & CEO recently bought kr74k worth of stock

Second quarter 2023 earnings: Revenues exceed analyst expectations

New minor risk - Profitability

Forecast breakeven date pushed back to 2025

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 24% Below Its Share Price

Price target decreased by 15% to kr31.00

First quarter 2023 earnings: Revenues exceed analyst expectations

Is Orexo (STO:ORX) A Risky Investment?

President & CEO recently bought kr189k worth of stock

Orexo AB (publ) Submits New Drug Application to FDA for OX124, A High-Dose Rescue Medication for Opioid Overdose

Full year 2022 earnings released: kr5.17 loss per share (vs kr6.51 loss in FY 2021)

Orexo AB (publ.) Initiates Exploratory Feasibility Studies of amorphOX with Two Leading Biopharmaceutical and Vaccine Companies

Orexo AB (publ) to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Consensus forecasts updated

Third quarter 2022 earnings released

Orexo AB (publ) Announces Last Patient Enrolled in Pivotal Study Evaluating the Efficacy of MODIA® in Combination with Sublingual Buprenorphine/ Naloxone for the Treatment of OUD

Orexo AB (publ) Appoints Edward Kim, M.D., as New Chief Medical Officer

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 92% Above Its Share Price

Orexo AB (publ), Annual General Meeting, Apr 18, 2023

Orexo Announces Positive Data from Phase 1 Clinical Study for OX640

Orexo AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

Would Orexo (STO:ORX) Be Better Off With Less Debt?

Consensus forecasts updated

Independent Director recently bought kr60k worth of stock

Second quarter 2022 earnings released

Orexo AB (Publ.) Announces Successfully Initiated the First Explorative Human Clinical Study for Ox640

Are Investors Undervaluing Orexo AB (publ) (STO:ORX) By 47%?

Consensus estimates of losses per share improve by 22%

First quarter 2022 earnings: Revenues in line with analyst expectations

Price target decreased to kr28.00

Orexo AB (publ) Announces Board Appointments

Is Orexo (STO:ORX) Using Too Much Debt?

Full year 2021 earnings: EPS exceeds analyst expectations

Director recently bought kr505k worth of stock

Consensus forecasts updated

Price target decreased to kr54.00

President & CEO recently bought kr243k worth of stock

Full year 2021 earnings: EPS exceeds analyst expectations

Orexo AB (publ) to Report Q4, 2022 Results on Jan 26, 2023

Orexo AB (Publ.) Develops Nasal Adrenaline Medication Based on the Novel Amorphox Platform

Orexo AB Provides Information About Its New Proprietary Drug Delivery Platform - Amorphox

Third quarter 2021 earnings released: kr1.52 loss per share (vs kr2.45 loss in 3Q 2020)

Consensus EPS estimates fall to -kr5.18

Second quarter 2021 earnings released: kr2.15 loss per share (vs kr0.94 loss in 2Q 2020)

Orexo AB (Publ) Pharmaceutical Pipeline Asset Ox124 Enters Pivotal Trial

Orexo Announces First Patient Enrolled in Pivotal Study Evaluating the Efficacy of Modia™ in Combination with Sublingual Buprenorphine/ Naloxone for the Treatment of OUD

Independent Director recently bought kr61k worth of stock

Independent Director recently bought kr103k worth of stock